` GTG (Genetic Technologies Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

GTG
vs
S
S&P/ASX 300

Over the past 12 months, GTG has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +4% growth.

Stocks Performance
GTG vs S&P/ASX 300

Loading
GTG
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GTG vs S&P/ASX 300

Loading
GTG
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
GTG vs S&P/ASX 300

Loading
GTG
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Genetic Technologies Ltd vs Peers

S&P/ASX 300
GTG
0KHE
TMO
DHR
LONN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Genetic Technologies Ltd
Glance View

Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.

GTG Intrinsic Value
0.027 AUD
Overvaluation 31%
Intrinsic Value
Price
Back to Top